Ask which product the statement describes
A provider may refer to sermorelin's FDA history while selling a compounded injection today. The important question is whether the statement concerns a particular historical drug product or the preparation now being offered. Sharing an ingredient name does not make those products identical in formulation, approval status or intended use.
Read the current product description, ask the dispensing pharmacy what is being prepared and obtain the prescriber's explanation of its status. An online page that says a substance was once approved should not leave the impression that the present bottle has automatically passed the same review. Our product listings keep compounded status separate from historical background.
What the historical record establishes
FDA's March 2013 notice discusses Geref injection products with distinct treatment and diagnostic indications. The treatment product concerned children with growth failure associated with idiopathic growth-hormone deficiency; the diagnostic preparation concerned evaluating pituitary growth-hormone secretion. Those indications are more specific than a general claim about improving adult energy or reversing aging.
The same notice records discontinuation and FDA's determination that the products were not removed from sale because of safety or effectiveness concerns. That conclusion corrects one possible misunderstanding about why a historical product disappeared. It does not approve every new use, every formulation containing sermorelin or every commercial statement made after the discontinuation.
What the determination does not establish
The notice allowed a path for qualifying abbreviated drug applications if other requirements were met. It did not transform compounded preparations into approved generic drugs. FDA's compounding guidance explicitly distinguishes approved generics from compounded medicines, which do not undergo the agency's premarket approval process for safety, effectiveness and quality.
That distinction matters when a provider uses phrases such as registered pharmacy or tested medication. Facility oversight and preparation testing address different questions from drug approval. Ask for the current product's exact identity and evidence instead of assuming that a historical brand name closes every regulatory or clinical question.
Adult care needs its own justification
An adult considering a wellness program needs an explanation of the proposed purpose and the evidence relevant to that use. Historical pediatric treatment or diagnostic indications cannot, on their own, demonstrate improved sleep, recovery, body composition or longevity for a contemporary adult plan. We do not treat those marketing outcomes as established by the Geref notice.
The Endocrine Society's adult growth-hormone-deficiency guideline describes a specific clinical evaluation and individualized treatment decisions. It is a separate source concerning a defined condition, not a blanket endorsement of commercial hormone optimization. A clinician should connect any diagnosis and proposed treatment to the person's actual history and findings.
Read provider FAQs with these distinctions in mind
IVY RX's current FAQ identifies the difference between Geref history and its compounded offering. iThriveMD also refers to the historical brand while describing present compounding. Those disclosures are useful starting points, but readers should still ask about the dispensed formulation, why it is proposed and how follow-up will assess benefit and problems.
Keep four questions separate: what the historical product was approved for, what the current preparation is, what evidence supports the proposed use and what the individual care plan includes. Clear answers are more useful than treating the word approved as a universal endorsement or treating discontinuation as proof of a safety withdrawal.
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.
- FDA determination on discontinued Geref products, March 4, 2013 Regulatory
- FDA: Understanding the Risks of Compounded Drugs Regulatory
- Endocrine Society: Evaluation and Treatment of Adult Growth Hormone Deficiency Clinical
- IVY RX: rendered sermorelin injection offer Provider
- iThriveMD: sermorelin treatment and billing options Provider